GLAXOSMITHKLINE FINANCE PLC
Get an alert when GLAXOSMITHKLINE FINANCE PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£1.9bn
-17.3% vs 2024
Net assets
£60bn
+0.2% vs 2024
Employees
—
Average over period
Profit before tax
£2.2bn
-18.8% vs 2024
Net assets
3-year trend · vs Financials median
GLAXOSMITHKLINE FINANCE PLC·Financials median
GLAXOSMITHKLINE FINANCE PLC·Financials median
GLAXOSMITHKLINE FINANCE PLC·Financials median
GLAXOSMITHKLINE FINANCE PLC·Financials median
GLAXOSMITHKLINE FINANCE PLC·Financials median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | — | — | — | — | |
| Operating profit | £198,480,000 | £267,051,000 | £165,526,000 | -38% | |
| Profit before tax | £1,698,480,000 | £2,667,051,000 | £2,165,526,000 | -18.8% | |
| Net profit | £1,651,652,000 | £2,599,793,000 | £2,124,147,000 | -18.3% | |
| Cash | £1,849,932,000 | £2,316,344,000 | £1,914,711,000 | -17.3% | |
| Total assets less current liabilities | £63,540,420,000 | £64,141,422,000 | £64,330,989,000 | +0.3% | |
| Net assets | £59,741,600,000 | £60,341,393,000 | £60,465,316,000 | +0.2% | |
| Equity | £59,741,600,000 | £60,341,393,000 | £60,465,316,000 | +0.2% | |
| Average employees | 0 | — | — | — | |
| Wages | — | — | — | — | |
| Directors' remuneration | £0 | £0 | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Return on capital employed | 0.3% | 0.4% | 0.3% | |
| Gearing (liabilities / total assets) | 60.6% | 60.9% | 61.4% | |
| Current ratio | 0.11x | 0.09x | 0.04x | |
| Interest cover | 0.05x | 0.06x | 0.04x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 3 times since incorporation
- GLAXOSMITHKLINE FINANCE PLC 2001-10-01 → present
- SMITHKLINE BEECHAM FINANCE P.L.C. 1989-10-03 → 2001-10-01
- BEECHAM FINANCE P L C 1980-12-31 → 1989-10-03
- BEECHAM FOODS LIMITED 1929-10-02 → 1980-12-31
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Having assessed the principal risks of the Company and other matters, the Directors are of the opinion that the current level of activity remains sustainable. The Directors in their considerations have included the accessibility of additional capital and the potential risk to liquidity.”
Group structure
- GLAXOSMITHKLINE FINANCE PLC · parent
- 1001508446 Ontario Inc. 100%
- 14245563 Canada Inc. 100%
- 14934792 Canada Inc. 100%
- 1506369 Alberta ULC 100%
- Action Potential Venture Capital Limited 100%
- Adechsa GmbH 100%
- Affinivax, Inc. 100%
- Aiolos Bio Limited 100%
- Aiolos Bio, Inc. 100%
- Allen & Hanburys Limited 100%
- Allen & Hanburys Pharmaceutical Nigeria Limited 100%
- Allen Pharmazeutika Gesellschaft m.b.H. 100%
- Amoun Pharmaceutical Industries Co. S.A.E. 90.71%
- ASC Oncology Schweiz AG in Liquidation 100%
- Beecham Group plc 100%
- Beecham Pharmaceuticals (Pte) Limited 100%
- Beecham Portuguesa- Produtos Farmaceuticos e Quimicos, Lda, 100%
- Bellus Health Inc 100%
- Biddle Sawyer Limited 75%
- Biovesta ilaçlari Ltd. Sti. 100%
- BP Asset IX, Inc. 100%
- Burroughs Wellcome International Limited 100%
- Cascan GmbH & Co. KG 100%
- Cellzome GmbH 100%
- Clarges Pharmaceuticals Trustees Limited 100%
- Colleen Corporation 100%
- Corixa Corporation 100%
- Dealcyber Limited 100%
- Desarrollo Energia Solar Alternativa S.L. 100%
- Domantis Limited 100%
- Duncan Pharmaceuticals Philippines Inc. 100%
- Edinburgh Pharmaceutical Industries Limited 100%
- Elsie Biotechnologies, Inc. 100%
- Eskaylab Limited 100%
- Etex Farmaceutica Ltda 100%
- Galvani Bioelectronics Inc. 55%
- Galvani Bioelectronics Limited 55%
- Glaxo Group Limited 100%
- Glaxo Kabushiki Kaisha 100%
- Glaxo New Zealand Pension Plan Trustee Limited 100%
- Glaxo Operations UK Limited 100%
- Glaxo Saudi Arabia Limited 100%
- Glaxo Verwaltungs GmbH 100%
- Glaxo Wellcome Farmaceutica, Limitada 100%
- Glaxo Wellcome International B.V. 100%
- Glaxo Wellcome Manufacturing Pte Ltd 100%
- Glaxo Wellcome Production 100%
- Glaxo Wellcome UK Limited 100%
- Glaxo Wellcome Vidhyasom Limited (in liquidation) 100%
- Glaxo Wellcome, S.A. 100%
- Glaxo, S.A. 100%
- Glaxochem (UK) Unlimited 100%
- Glaxochem Pte Ltd 100%
- GlaxoSmithKline - Produtos Farmaceuticos, Limitada 100%
- GlaxoSmithKline (Cambodia) Co., Ltd. 100%
- GlaxoSmithKline (China) Investment Co Ltd 100%
- GlaxoSmithKline (China) R&D Company Limited 100%
- GlaxoSmithKline (GSK) S.R.L. 100%
- GlaxoSmithKline (Ireland) Limited 100%
- GlaxoSmithKline (Israel) Ltd 100%
- GlaxoSmithKline (Private) Limited 100%
- GlaxoSmithKline (Thailand) Limited 100%
- GlaxoSmithKline (Tianjin) Co. Ltd 90%
- GlaxoSmithKline AB 100%
- GlaxoSmithKline AG 100%
- GlaxoSmithKline Algérie S.P.A. 99.99%
- GlaxoSmithKline Angola Unipessoal Limitada 100%
- GlaxoSmithKline AS 100%
- GlaxoSmithKline Australia Pty Ltd 100%
- GlaxoSmithKline B.V. 100%
- GlaxoSmithKline Beteiligungs GmbH 100%
- GlaxoSmithKline Biologicals Kft. 100%
- GlaxoSmithKline Biologicals S.A.S. 100%
- GlaxoSmithKline Biologicals SA 100%
- GlaxoSmithKline Brasil Limitada 100%
- GlaxoSmithKline Capital Inc. 100%
- GlaxoSmithKline Capital plc 100%
- GlaxoSmithKline Caribbean Limited 100%
- GlaxoSmithKline Chile Farmaceutica Limitada 100%
- GlaxoSmithKline Colombia S.A. 100%
- GlaxoSmithKline doo Beograd-Novi Beograd - U LIKVIDACIJI (In Liquidation) 100%
- GlaxoSmithKline Ecuador S.A. 100%
- GlaxoSmithKline El Salvador S.A. de C.V. 100%
- GlaxoSmithKline EOOD (Liquidated 10-Feb-2026) 100%
- GlaxoSmithKline Export Limited 100%
- GlaxoSmithKline Export Panama S.A. 100%
- GlaxoSmithKline Far East B.V. 100%
- GlaxoSmithKline GmbH & Co. KG 100%
- GlaxoSmithKline Guatemala S.A. 100%
- GlaxoSmithKline Holding AS 100%
- GlaxoSmithKline Holdings (Americas) Inc. 100%
- GlaxoSmithKline Holdings Pty Ltd 100%
- GlaxoSmithKline Honduras S.A. 100%
- GlaxoSmithKline IHC Limited 100%
- GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. 100%
- GlaxoSmithKline Inc. 100%
- GlaxoSmithKline Insurance Ltd. 100%
- GlaxoSmithKline Intellectual Property (No.2) Limited 100%
- GlaxoSmithKline Intellectual Property (No.3) Limited 100%
- GlaxoSmithKline Intellectual Property (No.4) Limited 100%
- GlaxoSmithKline Intellectual Property (No.5) Limited (In liquidation) 100%
- GlaxoSmithKline Intellectual Property Development Limited 100%
- GlaxoSmithKline Intellectual Property Holdings Limited 100%
- GlaxoSmithKline Intellectual Property Limited 100%
- GlaxoSmithKline Intellectual Property Management Limited 100%
- GlaxoSmithKline International Limited 100%
- GlaxoSmithKline Investigación y Desarrollo, S.L. 100%
- GlaxoSmithKline Investments Pty Ltd 100%
- GlaxoSmithKline Κ.Κ. 100%
- GlaxoSmithKline Korea Limited 100%
- GlaxoSmithKline Latin America, S.A. 100%
- GlaxoSmithKline Limited 100%
- GlaxoSmithKline Limited 100%
- GlaxoSmithKline LLC 100%
- GlaxoSmithKline Manufacturing SpA 100%
- GlaxoSmithKline Maroc S.A. 100%
- GlaxoSmithKline Mexico S.A. de C.V. 100%
- GlaxoSmithKline NZ Limited 100%
- GlaxoSmithKline Oy 100%
- GlaxoSmithKline Pakistan Limited 82.59%
- GlaxoSmithKline Peru S.A. 100%
- GlaxoSmithKline Pharma A/S 100%
- GlaxoSmithKline Pharma GmbH 100%
- GlaxoSmithKline Pharmaceutical Kenya Limited 100%
- GlaxoSmithKline Pharmaceutical Nigeria Limited 100%
- GlaxoSmithKline Pharmaceutical Sdn Bhd 100%
- GlaxoSmithKline Pharmaceuticals (Pvt) Ltd 100%
- GlaxoSmithKline Pharmaceuticals Costa Rica S.A 100%
- GlaxoSmithKline Pharmaceuticals Limited 75%
- GlaxoSmithKline Pharmaceuticals SA 100%
- GlaxoSmithKline Pharmaceuticals Ukraine LLC 100%
- GlaxoSmithKline Philippines, Inc. 100%
- GlaxoSmithKline Pte Ltd 100%
- GlaxoSmithKline Puerto Rico, Inc. 100%
- GlaxoSmithKline Republica Dominicana S.A. 100%
- GlaxoSmithKline Research & Development Limited 100%
- GlaxoSmithKline S.A. 100%
- GlaxoSmithKline S.A.E. 91.2%
- GlaxoSmithKline S.p.A. 100%
- GlaxoSmithKline s.r.o. 100%
- GlaxoSmithKline Services GmbH & Co. KG 100%
- GlaxoSmithKline Single Member Α.Ε.Β.Ε. 100%
- GlaxoSmithKline SL LLC 100%
- GlaxoSmithKline SL LP 100%
- GlaxoSmithKline South Africa (Pty) Limited 100%
- GlaxoSmithKline Trading Services Limited 100%
- GlaxoSmithKline Tunisia S.A.R.L. 100%
- GlaxoSmithKline UK Limited 100%
- GlaxoSmithKline Uruguay S.A. 100%
- GlaxoSmithKline US Trading Limited (In liquidation) 100%
- GlaxoSmithKline Venezuela C.A. 100%
- GlaxoSmithKline Vietnam Limited Liability Company 100%
- Groupe GlaxoSmithKline 100%
- GSK HGS Legacy LLC (Incorporated 16-Jan-2026) 100%
- GSK Biopharma Argentina S.A. 100%
- GSK Business Service Centre Sdn Bhd 100%
- GSK Capital B.V. 100%
- GSK Capital K.K. 100%
- GSK Commercial Sp. z o.o. 100%
- GSK d.o.o., Ljubljana 100%
- GSK Enterprise Management Co, Ltd 100%
- GSK Equity Investments, Limited 100%
- GSK Finance (No 2) Limited 100%
- GSK Finance (No.3) Limited (Dissolved 17-Feb-2026) 100%
- GSK India Global Services Private Limited 100%
- GSK International Holding and Finance BV 100%
- GSK Kazakhstan LLP 100%
- GSK Life Sciences FZE 100%
- GSK Pharma India Private Limited 100%
- GSK Pharma Vietnam Company Limited 100%
- GSK PSC Poland sp. z o.0. 100%
- GSK Regional Headquarters Company 100%
- GSK Services Sp z 0.0. 100%
- GSK Vaccines BV 100%
- GSK Vaccines GmbH 100%
- GSK Vaccines Institute for Global Health S.r.l. 100%
- GSK Vaccines S.r.l. 100%
- Human Genome Sciences, Inc. 100%
- ID Biomedical Corporation of Quebec 100%
- IDRX, INC. 100%
- InterPharma Dienstleistungen GmbH 100%
- J&J Technologies, LC 100%
- JSC GlaxoSmithKline Trading 100%
- Laboratoire GlaxoSmithKline 100%
- Laboratoire Pharmaceutique Algérien LPA Production SPA 100%
- Laboratoire Pharmaceutique Algérien SPA 100%
- Laboratoires Paucourt 100%
- Laboratoires Saint-Germain 100%
- Laboratorios Dermatologicos Darier, S.A de C.V. 100%
- Laboratorios Stiefel de Venezuela SA 100%
- Laboratorios Stiefel Ltda. 100%
- Limited Liability Company SmithKline Beecham-Biomed O.O.O. 97%
- Maxinutrition Limited (in liquidation) 100%
- Modern Pharma Trading Company L.L.C. 98.24%
- PT Glaxo Wellcome Indonesia 100%
- Setfirst Limited 100%
- Shanghai GlaxoSmithKline Pharmaceutical Co., Ltd. 100%
- Sitari Pharma, Inc. 100%
- Smith Kline & French Laboratories Limited (Dissolved 21-Jan-2026) 100%
- Smith Kline & French Portuguesa- Produtos Farmaceuticos, LDA 100%
- SmithKline Beecham (Bangladesh) Private Limited 100%
- SmithKline Beecham (Cork) Limited 100%
- SmithKline Beecham (Export) Limited 100%
- SmithKline Beecham (H) Limited 100%
- SmithKline Beecham (Investments) Limited 100%
- SmithKline Beecham Egypt L.L.C. 100%
- SmithKline Beecham Farma, S.A. 100%
- SmithKline Beecham Legacy H Limited 100%
- SmithKline Beecham Limited 100%
- SmithKline Beecham Marketing and Technical Services Limited 100%
- SmithKline Beecham Nominees Limited 100%
- SmithKline Beecham Overseas Limited 100%
- SmithKline Beecham Pension Plan Trustee Limited 100%
- SmithKline Beecham Pharma GmbH & Co KG 100%
- SmithKline Beecham Pharma Verwaltungs GmbH 100%
- SmithKline Beecham Pharmaceuticals (Pty) Limited 100%
- SmithKline Beecham Senior Executive Pension Plan Trustee Limited 100%
- Stiefel Egypt LLC 99%
- Stiefel GmbH & Co. KG 100%
- Stiefel Laboratories (U.K.) Ltd 100%
- Stiefel Laboratories Legacy (Ireland) Limited 100%
- Stiefel Laboratories Pte Limited 100%
- Stiefel Laboratories, Inc. 100%
- Stiefel Maroc SARL 100%
- Stiefel Research (Australia) Holdings Pty Ltd 100%
- Stiefel Research Australia Pty Ltd 100%
- Stiefel West Coast LLC 100%
- Strebor Inc. 100%
- Tesaro Bio GmbH (in liquidation) 100%
- Tesaro Bio Netherlands B.V 100%
- Tesaro Development, Ltd. 100%
- Tesaro UK Limited 100%
- Tesaro, Inc. 100%
- The Sydney Ross Co. 100%
- The Wellcome Foundation Limited 100%
- UCB Pharma Asia Pacific Sdn Bhd 100%
- Wellcome Consumer Healthcare Limited 100%
- Wellcome Limited 100%
Significant events
- “On 14 April 2026, the Company made a capital injection of $989m to GSK Finance (No. 2) Ltd to facilitate an acquisition. On the same day, GSK Finance (No. 2) Ltd. paid a dividend of $810m to the Company.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
5 active · 16 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| WHYTE, Victoria Anne | Secretary | 2002-01-18 | — | British |
| WALKER, Adam | Director | 2019-02-11 | Nov 1967 | British |
| EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Director | 2001-02-28 | — | — |
| GLAXO GROUP LIMITED | Corporate Director | 2001-02-28 | — | — |
| THE WELLCOME FOUNDATION LIMITED | Corporate Director | 2007-03-05 | — | — |
Show 16 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BALFOUR, Ian Main Ferguson | Secretary | — | 1994-01-01 |
| BICKNELL, Simon | Secretary | 2013-07-30 | 2014-03-10 |
| BRYANT, Karina Jane | Secretary | 1999-12-20 | 2002-01-18 |
| COOMBER, Caroline Daphne | Secretary | 1998-09-04 | 1999-12-20 |
| DILLON, Alison Marie | Secretary | — | 1998-09-04 |
| HORLER, Alison Marie | Secretary | 1994-01-01 | 1994-01-01 |
| WILBRAHAM, Simon Nicholas | Secretary | 1998-09-04 | 2001-02-28 |
| BLACKBURN, Paul Frederick | Director | 1999-01-01 | 2001-03-01 |
| BONFIELD, Andrew Robert John | Director | 1994-04-11 | 2000-12-27 |
| COLLUM, Hugh Robert | Director | — | 1998-12-31 |
| CROMPTON, Stephen Thomas | Director | — | 2001-03-01 |
| DEE, Nicholas Charles | Director | — | 2001-03-01 |
| DINGEMANS, Simon Paul | Director | 2011-04-01 | 2019-05-01 |
| HESLOP, Julian Spenser | Director | 2009-09-09 | 2011-03-31 |
| HOUSE, Philip Glyn | Director | — | 1994-04-11 |
| VICENTINI, Simone | Director | 2011-12-01 | 2019-02-11 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Glaxosmithkline Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 217 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-02-15 CC04 Statement of companys objects
- 2026-01-28 RESOLUTIONS Resolution
- 2026-01-28 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-14 | AA | accounts | Accounts with accounts type full | |
| 2026-04-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-02-15 | CC04 | change-of-constitution | Statement of companys objects | |
| 2026-01-28 | RESOLUTIONS | resolution | Resolution | |
| 2026-01-28 | MA | incorporation | Memorandum articles | |
| 2025-09-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-07-09 | AA | accounts | Accounts with accounts type full | |
| 2024-11-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-09-23 | CH03 | officers | Change person secretary company with change date | |
| 2024-09-17 | CH01 | officers | Change person director company with change date | |
| 2024-09-11 | CH02 | officers | Change corporate director company with change date | |
| 2024-09-11 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2024-09-11 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-07-18 | AD02 | address | Change sail address company with new address | |
| 2024-07-03 | AA | accounts | Accounts with accounts type full | |
| 2023-11-03 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-10-25 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-08-16 | CH02 | officers | Change corporate director company with change date | |
| 2023-07-10 | AA | accounts | Accounts with accounts type full | |
| 2022-10-14 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.